Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
50%(4 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_2
1
9%
Ph phase_1
10
91%

Phase Distribution

10

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
10(90.9%)
Phase 2Efficacy & side effects
1(9.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(3)

Detailed Status

Completed8
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 110 (90.9%)
Phase 21 (9.1%)

Trials by Status

terminated218%
withdrawn19%
completed873%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_1

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NCT04561245
completedphase_1

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT05134662
terminatedphase_1

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

NCT01625260
completedphase_1

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

NCT01326871
terminatedphase_1

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01670994
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04561245Phase 1

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

Completed
NCT05134662Phase 1

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Completed
NCT01625260Phase 1

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Terminated
NCT01326871Phase 1

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Completed
NCT01670994Phase 1

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Terminated
NCT05295875Phase 2

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Completed
NCT05006885Phase 1

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Completed
NCT05292911Phase 1

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Completed
NCT01029873Phase 1

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

Completed
NCT01478074Phase 1

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Withdrawn
NCT00496860Phase 1

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Completed

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11